Evelo Biosciences, Inc

(NASDAQ:EVLO)

Latest On Evelo Biosciences, Inc (EVLO):

Date/Time Type Description Signal Details
2023-04-26 17:27 ESTNewsEvelo slumps ~40% as eczema drug program abandoned after trial fails; cuts staffN/A
2023-03-16 17:34 ESTNewsEvelo Biosciences GAAP EPS of -$0.21 beats by $0.07N/A
2023-03-16 17:34 ESTNewsEvelo Biosciences, Inc. (EVLO) Q4 2022 Earnings Call TranscriptN/A
2023-02-01 16:29 ESTNewsEvelo drops 23% as atopic dermatitis trial fails; announces layoffsN/A
2022-11-15 18:40 ESTNewsEvelo Biosciences GAAP EPS of -$0.28 in-lineN/A
2022-08-12 02:07 ESTNewsEvelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 09:10 ESTNewsEvelo Biosciences GAAP EPS of -$0.40 beats by $0.03N/A
2022-08-11 09:10 ESTNewsEvelo Biosciences announces CEO succession planN/A
2022-07-18 11:37 ESTNewsMarella Thorell is the new finance chief of Evelo BiosciencesN/A
2022-06-06 20:17 ESTNewsEvelo Biosciences: Hope After Dilution?N/A
2022-05-25 16:48 ESTNewsEvelo Biosciences agrees over $79.2M direct offering of sharesN/A
2022-05-12 17:04 ESTNewsEvelo Biosciences GAAP EPS of -$0.56 beats by $0.04N/A
2022-04-23 04:04 ESTNewsEvelo Biosciences names former Alnylam, MyoKardia CEOs as strategic advisorsN/A
2022-04-14 22:21 ESTNewsEvelo stock falls as it puts EDP1867 eczema program on holdN/A
2022-03-25 22:06 ESTNewsEvelo Biosciences, Inc. (EVLO) CEO Simba Gill On Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-25 22:05 ESTNewsEvelo Biosciences spikes after 4Q 2021 earningsN/A
2022-03-24 10:33 ESTNewsEvelo Biosciences GAAP EPS of -$0.54 beats by $0.08N/A
2022-02-28 10:16 ESTNewsEvelo psoriasis therapy EDP1815 shows durable response in phase 2 trial follow upN/A
2022-02-17 16:21 ESTNewsEvelo Biosciences begins dosing in phase 2 trial of EDP1815 for eczemaN/A
2022-02-07 22:22 ESTNewsEvelo Biosciences posts biomarker data from Phase 2 psoriasis studyN/A
2021-12-14 14:06 ESTNewsEvelo Biosciences picked for addition to Nasdaq Biotechnology IndexN/A
2021-11-01 19:01 ESTNewsEvelo Biosciences climbs 22% as Chardan upgrades shares to buyN/A
2021-10-28 20:59 ESTNewsEvelo Biosciences EPS misses by $0.09N/A
2021-10-28 20:57 ESTNewsEvelo Biosciences, Inc. (EVLO) CEO Simba Gill On Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-13 00:38 ESTNewsWarning: EVLO is at high risk of performing badlyN/A
2021-10-07 10:07 ESTNewsEVLO is at high risk of performing badlyN/A
2021-09-27 17:14 ESTNewsWarning: EVLO has been downgraded to Very BearishN/A
2021-09-27 17:08 ESTNewsEvelo Bio reports positive EDP1815 data in mid-stage psoriasis studyN/A
2021-09-27 17:07 ESTNewsEvelo Bio shares down 4% despite positive phase 2 psoriasis dataN/A
2021-09-25 02:20 ESTNewsEvelo Biosciences (EVLO) Investor Presentation - SlideshowN/A
2021-09-23 02:29 ESTNewsWarning: EVLO has been downgraded to Very Bearish.N/A
2021-09-10 00:33 ESTNewsEvelo Biosciences issued new composition of matter patent in U.S.N/A
2021-09-04 10:29 ESTNewsInnate Pharma, Adagio top weekly healthcare gainers, Acasti Pharma, Forte Biosciences trailN/A
2021-09-03 15:12 ESTNewsEvelo BioSciences down 14% ahead of psoriasis candidate EDP1815 data readoutN/A
2021-08-01 02:35 ESTNewsEvelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2021 Results - Earnings Call TranscriptN/A
2021-05-01 08:12 ESTNewsEvelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call TranscriptN/A
2021-04-29 12:34 ESTNewsEvelo Biosciences EPS misses by $0.03N/A
2021-04-20 23:23 ESTNewsEvelo Biosciences releases complete dataset from early stage atopic dermatitis studyN/A
2021-04-15 19:19 ESTNewsEvelo Biosciences names industry veteran as CFON/A
2021-04-12 19:33 ESTNewsTwist Bioscience and Codexis in focus as Piper Sandler upbeat on synthetic biology, and more in today’s analyst actionN/A
2021-03-23 22:58 ESTNewsEvelo Bio inks EDP1815 development deal for inflammatory diseases & COVID-19N/A
2021-03-16 20:47 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.5 to $20.2.Neutral
2021-03-11 11:34 ESTAnalyst RatingThe Analyst Target Price has increased from $20.33 to $21.5.Buy
2021-03-10 11:29 ESTFinancialsCompany financials have been released.Neutral
2021-03-10 11:29 ESTEarnings EstimateAn EPS average of -$1.77 is estimated for the 2022 year.Sell
2021-03-10 11:29 ESTEarnings EstimateAn EPS average of -$0.55 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-09 16:24 ESTNewsEvelo Biosciences, Inc. 2020 Q4 - Results - Earnings Call PresentationN/A
2021-03-09 16:24 ESTNewsEvelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call TranscriptN/A
2021-01-29 17:27 ESTNewsEvelo Bio secures ~$67.5M capital raiseN/A
2021-01-29 07:40 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.5 to $20.33.Neutral

About Evelo Biosciences, Inc (EVLO):

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

EVLO Quotes by TradingView

See Advanced Chart

General

  • Name Evelo Biosciences, Inc
  • Symbol EVLO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 90
  • Fiscal Year EndDecember
  • IPO Date2018-05-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.evelobio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 23.95
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.13
  • Next Year EPS Estimate -$2.05
  • Next Quarter EPS Estimate -$0.45
  • Return on Assets -63%
  • Return on Equity -207%
  • Earnings Per Share -$2.27
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 715.22 million
  • EBITDA -73155000
  • Analyst Target Price $20.2
  • Book Value Per Share $0.64
View More

Share Statistics

  • Shares Outstanding 53.33 million
  • Shares Float 27 million
  • % Held by Insiders 52%
  • % Held by Institutions 87.46%
  • Shares Short 2.34 million
  • Shares Short Prior Month 2.63 million
  • Short Ratio 7.58
  • Short % of Float 8%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 1.31
  • 52 Week High $19.93
  • 52 Week Low $3.23
  • 50 Day Moving Average 14.34
  • 200 Day Moving Average 8.93
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Evelo Biosciences, Inc (EVLO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Evelo Biosciences, Inc (EVLO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.57-$0.53-7.75%
2020-09-302020-10-29$N/A-$0.45-$0.5010%
2020-06-302020-07-30$N/A-$0.63-$0.7211.89%
2020-03-312020-05-11$N/A-$0.71-$0.71-0.71%
2019-12-312020-02-13$N/A-$0.70-$0.58-21.74%
2019-09-302019-11-05$N/A-$0.67-$0.66-1.52%
2019-06-302019-08-06$N/A-$0.65-$0.58-11.66%
2019-03-312019-05-02$N/A-$0.64-$0.51-25.49%
2018-12-312019-02-14$N/A-$0.49-$0.6625.76%
2018-09-302018-11-01$N/A-$0.50-$0.547.41%
2018-06-302018-08-02$N/A-$0.85-$0.34-150%
2018-03-312018-05-09$N/A-$0.81

Evelo Biosciences, Inc (EVLO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 117.12 million N/A N/A 17.42 million 16.38 million
Income Before Tax -28.86 million N/A N/A -22.98 million -22.41 million
Selling General Administrative 38.46 million N/A N/A 5.84 million 6.29 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -28.86 million N/A N/A -22.77 million -22.67 million
Operating Income -28.2 million N/A N/A -23.26 million -22.67 million
Income Tax Expense 188000 67000 89000 N/A 190000
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 466000 261000
Net Income From Continuing Operations -29.05 million N/A N/A -23.04 million -22.6 million
Net Income Applicable to Common Shares -29.05 million -20.92 million -20.65 million N/A -22.6 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -429000 N/A 4 million
Change to Liabilities -707000 2.25 million N/A -675000 -1.23 million
Total Cash Flow from Investing Activities -261000 -216000 N/A -463000 2.91 million
Net Borrowings 10 million N/A N/A N/A 4.48 million
Total Cash Flow from Financial Activities N/A N/A 226000 229000 4.56 million
Change to Operating Activities 362000 -1.17 million N/A 1.77 million 500000
Change in Cash N/A N/A -19.72 million -19.23 million -12.16 million
Total Cash from Operating Activities -18.22 million -16.38 million -19.52 million -18.99 million -19.64 million
Depreciation N/A N/A 491000 500000 461000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A 56000
Change to Net Income 2.59 million 2.66 million N/A 2.01 million 2.27 million
Capital Expenditures N/A N/A 435000 463000 1.09 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 60.15 million N/A N/A 43.8 million 30.72 million
Total Stockholder Equity 30.49 million N/A N/A 39.34 million 60.2 million
Other Current Liabilities 2.14 million N/A N/A 408000 365000
Total Assets 90.64 million N/A N/A 83.15 million 90.92 million
Common Stock 47000 50.43 million 69.21 million N/A 32000
Other Current Assets 2.12 million N/A N/A N/A N/A
Retained Earnings -292.52 million N/A N/A -221.89 million -198.85 million
Other Liabilities N/A 432000 303000 N/A 1.35 million
Other Assets N/A 4.48 million 4.11 million N/A 1.57 million
Cash 68.86 million N/A N/A 58.12 million 77.83 million
Total Current Liabilities 19.83 million 11.94 million N/A 12.46 million 9.74 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 7.48 million 18.78 million 19.62 million N/A 8.34 million
Total Current Assets 70.98 million 81.58 million N/A 60.99 million 81.01 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 30.49 million 50.43 million 69.21 million N/A 60.2 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt 30.05 million N/A N/A 19.72 million 19.63 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 17.7 million 11.94 million N/A 1.21 million 620000

Evelo Biosciences, Inc (EVLO) Chart:

Evelo Biosciences, Inc (EVLO) News:

Below you will find a list of latest news for Evelo Biosciences, Inc (EVLO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Evelo Biosciences, Inc (EVLO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest EVLO Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST73$1.985
Jun 13, 2022 7:59 PM EST78$1.99
Jun 13, 2022 7:59 PM EST59$1.99
Jun 13, 2022 7:59 PM EST500$1.99
Jun 13, 2022 7:59 PM EST58$1.99

Evelo Biosciences, Inc (EVLO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924320018150/0000899243-20-018150-index.htm
2019-06-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1694665/000000000019009366/0000000000-19-009366-index.htm
2018-07-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1694665/000031506618002092/0000315066-18-002092-index.htm
2018-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1694665/000031506618002535/0000315066-18-002535-index.htm
2019-01-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1694665/000031506619000031/0000315066-19-000031-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1694665/000031506620000934/0000315066-20-000934-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011962/0000899243-18-011962-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011963/0000899243-18-011963-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011964/0000899243-18-011964-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011966/0000899243-18-011966-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011967/0000899243-18-011967-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011969/0000899243-18-011969-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011970/0000899243-18-011970-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011975/0000899243-18-011975-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011976/0000899243-18-011976-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011977/0000899243-18-011977-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318011978/0000899243-18-011978-index.htm
2018-05-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318012414/0000899243-18-012414-index.htm
2018-05-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318012415/0000899243-18-012415-index.htm
2018-05-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318012419/0000899243-18-012419-index.htm
2018-05-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318012420/0000899243-18-012420-index.htm
2018-05-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318012422/0000899243-18-012422-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318013013/0000899243-18-013013-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924318013014/0000899243-18-013014-index.htm
2020-07-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924320018149/0000899243-20-018149-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000089924320018150/0000899243-20-018150-index.htm
2018-04-13S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1694665/000119312518116927/0001193125-18-116927-index.htm
2018-04-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1694665/000119312518116938/0001193125-18-116938-index.htm
2018-04-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1694665/000119312518126511/0001193125-18-126511-index.htm
2018-04-308-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1694665/000119312518140593/0001193125-18-140593-index.htm
2018-04-30S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1694665/000119312518140612/0001193125-18-140612-index.htm
2018-05-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1694665/000119312518152447/0001193125-18-152447-index.htm
2018-05-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1694665/000119312518152453/0001193125-18-152453-index.htm
2018-05-09424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1694665/000119312518157585/0001193125-18-157585-index.htm
2018-05-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1694665/000119312518159364/0001193125-18-159364-index.htm
2018-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000119312518160865/0001193125-18-160865-index.htm
2018-05-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1694665/000119312518167090/0001193125-18-167090-index.htm
2018-05-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1694665/000119312518168931/0001193125-18-168931-index.htm
2018-05-21SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1694665/000119312518169675/0001193125-18-169675-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000119312518179502/0001193125-18-179502-index.htm
2018-05-3110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000119312518180379/0001193125-18-180379-index.htm
2018-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000119312518235695/0001193125-18-235695-index.htm
2018-08-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000119312518236655/0001193125-18-236655-index.htm
2020-06-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1694665/000119312520177632/0001193125-20-177632-index.htm
2020-06-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1694665/000119312520178917/0001193125-20-178917-index.htm
2020-07-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1694665/000119312520185285/0001193125-20-185285-index.htm
2018-05-08CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1694665/000135445718000133/0001354457-18-000133-index.htm
2018-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466518000004/0001694665-18-000004-index.htm
2018-11-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466518000006/0001694665-18-000006-index.htm
2018-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466518000008/0001694665-18-000008-index.htm
2018-11-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000169466518000010/0001694665-18-000010-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000002/0001694665-19-000002-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000004/0001694665-19-000004-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000006/0001694665-19-000006-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000010/0001694665-19-000010-index.htm
2019-02-1510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1694665/000169466519000013/0001694665-19-000013-index.htm
2019-04-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000016/0001694665-19-000016-index.htm
2019-04-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000017/0001694665-19-000017-index.htm
2019-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000022/0001694665-19-000022-index.htm
2019-05-0310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000169466519000024/0001694665-19-000024-index.htm
2019-06-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1694665/000169466519000028/0001694665-19-000028-index.htm
2019-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000030/0001694665-19-000030-index.htm
2019-06-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000032/0001694665-19-000032-index.htm
2019-06-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1694665/000169466519000035/0001694665-19-000035-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000037/0001694665-19-000037-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000039/0001694665-19-000039-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000041/0001694665-19-000041-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000043/0001694665-19-000043-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000045/0001694665-19-000045-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000047/0001694665-19-000047-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000049/0001694665-19-000049-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000051/0001694665-19-000051-index.htm
2019-06-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000053/0001694665-19-000053-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000055/0001694665-19-000055-index.htm
2019-07-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000058/0001694665-19-000058-index.htm
2019-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000064/0001694665-19-000064-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000067/0001694665-19-000067-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000169466519000069/0001694665-19-000069-index.htm
2019-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000071/0001694665-19-000071-index.htm
2019-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000073/0001694665-19-000073-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000076/0001694665-19-000076-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000169466519000078/0001694665-19-000078-index.htm
2019-12-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000080/0001694665-19-000080-index.htm
2019-12-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000082/0001694665-19-000082-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466519000084/0001694665-19-000084-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000002/0001694665-20-000002-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000004/0001694665-20-000004-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000006/0001694665-20-000006-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000008/0001694665-20-000008-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000010/0001694665-20-000010-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000015/0001694665-20-000015-index.htm
2020-02-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1694665/000169466520000017/0001694665-20-000017-index.htm
2020-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000020/0001694665-20-000020-index.htm
2020-03-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000022/0001694665-20-000022-index.htm
2020-04-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000024/0001694665-20-000024-index.htm
2020-04-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000026/0001694665-20-000026-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000031/0001694665-20-000031-index.htm
2020-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000033/0001694665-20-000033-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000035/0001694665-20-000035-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000037/0001694665-20-000037-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000169466520000039/0001694665-20-000039-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000042/0001694665-20-000042-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000046/0001694665-20-000046-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000054/0001694665-20-000054-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000055/0001694665-20-000055-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000056/0001694665-20-000056-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000057/0001694665-20-000057-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000058/0001694665-20-000058-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000068/0001694665-20-000068-index.htm
2020-07-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000070/0001694665-20-000070-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000074/0001694665-20-000074-index.htm
2020-07-3110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000169466520000079/0001694665-20-000079-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000081/0001694665-20-000081-index.htm
2020-10-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000083/0001694665-20-000083-index.htm
2020-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1694665/000169466520000087/0001694665-20-000087-index.htm
2020-10-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1694665/000169466520000090/0001694665-20-000090-index.htm
2018-05-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000172202418000004/0001722024-18-000004-index.htm
2018-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1694665/000172202418000006/0001722024-18-000006-index.htm
2018-05-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1694665/999999999518001169/9999999995-18-001169-index.htm
2019-06-06EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1694665/999999999519001300/9999999995-19-001300-index.htm
2018-05-09CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1694665/999999999718005622/9999999997-18-005622-index.htm

Evelo Biosciences, Inc (EVLO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Evelo Biosciences, Inc (EVLO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 52%
Institutional Ownership: 8746%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-28David R EpsteinDirectorBuy1,000.004.344,340.001,000.00https://www.sec.gov/Archives/edgar/data/1694665/000169466520000081/0001694665-20-000081-index.htm
2020-08-31David R EpsteinDirectorBuy1,000.004.584,580.0010,000.00https://www.sec.gov/Archives/edgar/data/1694665/000169466520000081/0001694665-20-000081-index.htm
2020-06-29Flagship Ventures Fund IV General Partner LLC10% Share HolderBuy1,333,333.003.754,999,998.751,333,333.00https://www.sec.gov/Archives/edgar/data/1694665/000089924320018150/0000899243-20-018150-index.htm
2018-05-11Flagship Ventures Fund IV General Partner LLC10% Share HolderBuy281,250.0016.004,500,000.0018,233,403.00https://www.sec.gov/Archives/edgar/data/1694665/000089924318013014/0000899243-18-013014-index.htm
2018-05-11Flagship Ventures Fund V General Partner LLC10% Share HolderBuy281,250.0016.004,500,000.0018,233,403.00https://www.sec.gov/Archives/edgar/data/1694665/000089924318013013/0000899243-18-013013-index.htm
2020-06-29Flagship Ventures Fund IV General Partner LLC10% Share HolderBuy1,333,333.003.754,999,998.753,170,169.00https://www.sec.gov/Archives/edgar/data/1694665/000089924320018150/0000899243-20-018150-index.htm
2020-06-29Flagship Ventures Fund IV General Partner LLC10% Share HolderBuy1,666,667.003.756,250,001.254,079,032.00https://www.sec.gov/Archives/edgar/data/1694665/000089924320018150/0000899243-20-018150-index.htm
2020-08-28David R EpsteinDirectorBuy3,248.004.4014,291.204,248.00https://www.sec.gov/Archives/edgar/data/1694665/000169466520000081/0001694665-20-000081-index.htm
2020-08-31David R EpsteinDirectorBuy2,752.004.4612,273.927,000.00https://www.sec.gov/Archives/edgar/data/1694665/000169466520000081/0001694665-20-000081-index.htm
2020-06-29Flagship Ventures Fund IV General Partner LLC10% Share HolderBuy333,333.003.751,249,998.75782,244.00https://www.sec.gov/Archives/edgar/data/1694665/000089924320018150/0000899243-20-018150-index.htm
2020-08-31David R EpsteinDirectorBuy1,000.004.474,470.008,000.00https://www.sec.gov/Archives/edgar/data/1694665/000169466520000081/0001694665-20-000081-index.htm
2020-08-31David R EpsteinDirectorBuy1,000.004.484,480.009,000.00https://www.sec.gov/Archives/edgar/data/1694665/000169466520000081/0001694665-20-000081-index.htm